Es wurden 83 Technologieangebote gefunden

Bisphosphonates as Potential Drug Candidates for Inflammatory Lung Diseases


15.02.2012
| Ref.Nr. 09061
Life Science › Pharma&Biotech

Biphosphonate with a prolonged carbon chain.Recent findings in animal models underline the potential role of the acid sphingomyelinase (aSMase) as an important drug target in inflammatory lung diseases like acute lung injury (ALI) - the main cause of death in intensive care units -, acute respiratory distress syndrome (ARDS), lung emphysema, and cystic fibrosis.

The invention offers simple geminal bisphosphonates with a prolonged carbon chain as potent and selective inhibitors of the acid sphingomyelinase. The compounds can be synthesized in a one-step or two-step procedure and show clear inhibition of cell death in vitro. First ex vivo data in rats show a reduction of platelet activating factor (PAF) – induced pulmonary edema in the presence of the bisphosphonates by at least 50 percent. Aerosols of bisphosphonates may be possible applicants for the treatment of pulmonary diseases.

Besides their use in inflammatory lung diseases the bisphosphonates with prolonged carbon chain may be used as a treatment option for cystic fibrosis and atherosclerosis.


IP Rights
EP Application (08/2009).
PCT Application (08/2010).
A PCT application was filed in August 2010.

Patent Owner
Humboldt-Universität zu Berlin
Rheinisch-Westfälische
Technische Hochschule Aachen (RWTH)

Application Area:
Drug candidates for the treatment of inflammatory lung diseases, cystic fibrosis and atherosclerosis.
Development Stage: Ex vivo
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
Suitable Industry: Pharmaceuticals
Benefits:
  • Neutral sphingomyelinase is not influenced
  • First ex-vivo data in a PAF-induced edema rat model showed clear edema reduction by 50percent
  • Inhibition of dexamethasone induced apoptosis was proven in vitro
  • Substances can easily be synthesized in a one-step or two-step procedure
  • Prolongation from 6 to 8 C-atoms shows 40times higher inhibition rate

 

Porous Metal Oxide Films


06.01.2012
| Ref.Nr. 09068
Physics&Engineering

SEM image of a macroporous network (Sokolov, Paul, Krähnert. 2009)Background
Thin porous metal oxide films offer unique physical, electrical and magnetic properties with applications in various fields including catalysis, gas sensing and separation, power storage and generation as well as biology and medicine. Currently known synthesis techniques for metal oxide films with templated porosity (e.g. dip-coating, spin-coating) show significant limitations when they are faced with large substrates and/or substrates with a micro-structured surface.

Technology
We offer an improved method for the production of porous metal oxide films on a substrate using template assisted electrostatic spray deposition (ESD). It overcomes all known problems of current technologies like dip- and spin coating.This novel method is able to produce unisized mesoporous and macroporous films by directly controlling the size and concentration of the pore forming organic templates in an initially formed precursor solution.


IP Rights

PCT Application with priority on October 2009

Patent Owner
Technische Universität Berlin, Germany

PDF Download

Application Area:
Catalysis, Sensors (gas sensors), (Dye sensitized) solar cells, Templates, Displays
Development Stage: Product
Schlagworte: Metal oxide, Pore, Porous,
Weitere Kategorien: Catalysis, Physics & Engineering
Bild des Benutzers Jeanne Trommer
Licensing Manager: Jeanne Trommer
T +49 30 2125 4831
F +49 30 2125 4822
Suitable Industry: Chemistry, Photovoltaic, Electronic, Optoelectronic
Benefits:

  • Hierarchically structured meso- and macroporous films
  • Control of pore morphology (volume, size, distribution, connectivity)
  • Pores can be coated with catalytic active material
  • Various substrates can be used
  • Coating of large substrates
  • Easy transfer to industrial applications
  • Production under room conditions

C3bot Peptides as Drugs for the Treatment of Traumatic or Degenerative Neuronal Injury


21.12.2011
| Ref.Nr. 08167
Life Science › Pharma&Biotech

Figure : Neurocyte Picture: Höltje et al. 2009Background
Peptide fragments of the C3 exoenzyme of Clostridium botulinum have been found to have neuritogenic effects on neurons as well as regenerative proper-ties in an animal model (mouse). The peptides represent promising drug candidates for the treatment of neurodegenerative disorders such as Morbus Alzheimer, Parkinson, Huntington chorea but also for spinal cord injury and traumatic brain injury.enic effects on neurons as well as regenerative properties in an animal model (mouse).

Technology
We offer neuron-specific short peptides for the treatment of neurodegene-rative disorders. Whereas a 26mer peptide stimulates both, dendritic and axonal growth, a 15mer peptide selectively promotes axonal growth. Both, the 15mer and the 26mer peptide trigger a strong transient activation of RhoA which mimics the physiological conditions of RhoA activation / inactivation cycles.
These properties make the peptides suitable for repeated administration and long term treatments. As the peptides only act on neurons and not on microglia or astrocytes, there is no risk for neuronal inflammation or glia scar formation.

 

IP Rights
PCT application in 2010
National applications in USA/Europe in 2011

Patent Owner
Charité – Universitätsmedizin Berlin
Hannover Medical School

Application Area:
Drug candidates for the treatment of neurodegenerative disorders
Development Stage: In vitro / in vivo
Weitere Kategorien: Life Science, Pharma & Biotech
Bild des Benutzers Dr. Janin Hofmann
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
Benefits:
  • Physiological acting neuritogenic drug – small size and effective in nanomolar concentrations
  • Act neuron-specific -> reduced risk for neuronal inflammation or glia scar formation
  • Short peptides with low antigenicity and good kinetics
  • Broad application areas: Spinal cord injury, traumatic brain injury, Morbus Alzheimer, Parkinson, Huntington Chorea, etc.
  • In vivo data on spinal cord injury model show regenerative properties

Cytokinin Receptor Antagonists and Compositions Containing these Derivatives


08.12.2011
| Ref.Nr. 07114
Life Science › Nutrition

Generel formular of alylbenzylamino Picture: WO 2009/043320 A2 Background
Cytokinins are plant hormones involved in cell division, shoot meristem and leaf formation, chloroplast biogenesis, and senescence. The development of agonists and antagonists with a particular physiological effect is useful in mechanism-of-action studies of biologically active natural products. The potent naturally occurring cytokinin N6-isopentenyladenine served as the basis for initial structure-activity studies.

Technology
We offer substituted 6-(alkylbenzylamino)-purin derivatives as cytokinin receptor antagonists to provide cytokinin analogons for growth regulation in plants and to offer the possibility for a specific selectivity for cytokinin receptors without being toxic for animal cells. The derivatives can be used to influence morphology, leading to:
  • Increased root growth, fruit or grain size
  • Stimulation of root branching and enhanced number of lateral roots
  • Accelerated seed germination
  • Enhanced yield and quality of crops

 
IP Rights
Czech Patent Application was filed in 2007
PCT Patent Application was filed in 2008
National applications filed in USA and Europe

Patent Owner

  • Freie Universität Berlin
  • Palacky University Olomouc (CZ)
Application Area:
Applicable as plant growth regulator
Development Stage: Green house (plant model Arabidopsis thaliana)
Weitere Kategorien: Life Science, Nutrition
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
Suitable Industry: Agriculture industry
Benefits:
  • Non toxic for animal cells
  • Efficiency is proven in various test systems
  • Suitable regulator for proliferation and morphogenesis in tissue culture

Novel Screening Method for Agents suitable for Therapy of Alzheimer´s Disease


28.10.2011
| Ref.Nr. 07081
Life Science › Pharma&Biotech

Technology
We offer a screening method that allows the detection of novel drug candidates for the prophylaxis and causative therapy of Alzheimer’s Disease.

The identified drugs influence the substrat-enzyme interaction between amyloid precursor protein (APP) and gamma-secretase in a way that less Amyloid-β-peptide (Aβ42) is produced. Furthermore they have the ability to bind selectively and with high affinity the APP-GxxxG-motif and can pass the blood-brain barrier. It was shown that a drug capable of binding the APP GxxxG motif is weakening or inhibiting the dimerization of the APP trans-membrane sequence, leading to a decreased generation of Aβ42.

IP Rights
EP patent application was filed in November 2007.
PCT patent application was filed in November 2008.
US application was filed in April 2010.

Origin
Freie Universiät Berlin
Application Area:
Drug screening
Development Stage: Product
Bild des Benutzers Rafaela Kunz
Licensing Manager: Rafaela Kunz
T +49 30 2125 4825
F +49 30 2125 4822
Suitable Industry: Pharmaceuticals, Research & Development
Benefits:
  • Reliable, rapid, and easy screening assay for the identification of novel drug candidates
  • Applicable to blood samples

Assay for the Diagnosis of Alzheimer’s Disease based on the Determination of the Ratio of Aß38:Aß42


28.10.2011
| Ref.Nr. 06021
Life Science › Pharma&Biotech

Backgorund
Processing of the amyloid precursor protein (APP) by ß-and γ -secretases leads to the generation of amyloid-ß (Aß) peptides, which are the toxic agents in the pathogenesis of Alzheimer`s Disease. γ –secretase cleaves at variable sites producing Aß peptides with different C-termini, of which particularly Aß42 contributes to cytotoxicity and amyloid accumulation in Alzheimer Disease.

We discovered that dimerization of the APP trans-membrane sequence is mediated by glycine residues G29 and G33 of the three consecutive GxxxG motifs promoting helix-helix interactions. Mutations at the glycine positions attenuate the TMS dimerization strength and specifically reduce generation of Aß42. The level of reduced Aß42 is counterbalanced by increased Aß38, whereas the level of Aß40 remains unaffected.

Technology
We offer a novel assay for the diagnosis of early and late stages of Alzheimer’s Disease. The assay is very easy to use and allows a rapid and reliable detection of Aß38:Aß42. The ratio is used to make the diagnosis.

IP Rights
European Patent application was filed in June 2006.
PCT application was filed in April 2007.
Patent applications were filed in US, JP, IN, CN, CA, FR, GB, IT, ES, DE.

Origin
Freie Universität Berlin

 

Application Area:
Diagnosis of Alzheimer disease at all stages
Development Stage: Product
Bild des Benutzers Rafaela Kunz
Licensing Manager: Rafaela Kunz
T +49 30 2125 4825
F +49 30 2125 4822
Suitable Industry: Diagnostics, Pharmaceuticals
Benefits:
  • Suitable for diagnosing Alzheimer at early stage of disease
  • Reliable, easy, and rapid diagnosis
  • Screening of blood samples

Highly Efficient Light Emitters - The Route to Green Lasers


25.08.2011
| Ref.Nr. 06094
Physics&Engineering
Background
The emission of green laser light is of great importance for several applications and procedures in biology, medicine and multimedia. A powerful green laser could revolutionize the market for portable beamers. So far, semiconductor based light emitters, such as laser pointers, convert infrared light by frequency doubling into green light. A significant drawback of this technique is the loss of power and efficiency.

Technology
We offer green light emitting semiconductor devices including for example a green laser. The use of ZnCdO as a semiconductor material allows direct emission of green light without frequency doubling.

IP Rights
German Patent Application

Patent Owner

Humboldt-Universität zu Berlin, Germany

Application Area:
Green lasers, Laser diodes
Development Stage: Demonstrator
Bild des Benutzers Dr. Kirk Haselton
Licensing Manager: Dr. Kirk Haselton
T +49 30 2125 4842
F +49 30 2125 4822
Benefits:
  • Direct Green light emission (band gap 2.2 eV - 2.5 eV)
  • No frequency doubling involved
  • No loss of efficiency
  • High degree of crystalline perfection
  • High stable semiconductor material
  • Small, low cost device

     

Terahertz Quantum Cascade Lasers


25.08.2011
| Ref.Nr. 09018
Physics&Engineering

Background
Quantum Cascade Lasers (QCLs) are currently the best electrically-pumped sources of Terahertz (THz) radiation regarding output power, linewidth, operating temperatures and efficiency. THz QCLs offer a wide field of applications ranging from astrophysics and security screening to ultrafast spectroscopy in chemistry or biology. For all these applications THz QCLs which can operate at moderate temperature are desired.

Technology
The invention offers a THz Quantum Cascade Laser with improved temperature performance. The THz QCL uses a strain-compensated (Al, Ga, In)As material grown on InP substrates.

IP Rights

PCT Application

Patent Owner
Humboldt-Universität zu Berlin, Germany
University of Texas, USA

Application Area:
Spectroscopy (Chemistry, Biochemistry, Astrophysics), Medical Imaging, Detectors, Sensors
Development Stage: Concept
Bild des Benutzers Dr. Kirk Haselton
Licensing Manager: Dr. Kirk Haselton
T +49 30 2125 4842
F +49 30 2125 4822
Suitable Industry: Security Industry, Chemical Industry, Medical Industry
Benefits:
  • Operating frequencies: 0.8 THz - 5 THz
  • Operating temperature: 240K minimum
  • Operating temperature can be achieved using thermoelectric coolers
  • Improved laser gain compared to common THz QCLs

     

Catalytic Nano-Pen for Cutting Graphene


25.08.2011
| Ref.Nr. 08133
Physics&Engineering

Scheme (left) and scanning tunneling microscope (STM) image of a graphene trench made by the catalytic nano-pen Background
Graphene, a monoatomic layer of graphite, is a promising candidate for future (nano)electronic applications. Currently however there are no techniques available for reproducibly cutting graphene with nanometer precision.

Technology
We provide a catalytic Nano-Pen for high speed trench channeling of mono- and multilayer graphene using silver nanoparticles in an ambient environment and at elevated temperatures. A silver nanoparticle located at a graphene edge catalyzes oxidation of neighboring carbon atoms, thereby burning a trench into the graphene layer.

IP Rights
German Patent DE102008053691B3
US Patent Application

Patent Owner
Humboldt-Universität zu Berlin, Germany

Application Area:
Transparent and flexible electrodes, Flexible Solar cells, Flexible displays, Transistors, Memories
Development Stage: Proof of Concept
Schlagworte: Carbon, Graphene, Lithography,
Weitere Kategorien: Catalysis, Physics & Engineering
Bild des Benutzers Dr. Kirk Haselton
Licensing Manager: Dr. Kirk Haselton
T +49 30 2125 4842
F +49 30 2125 4822
Suitable Industry: (Nano)electronic, Optoelectronic, Consumer Electronic
Benefits:
  • high-precision lithography on graphene
  • cutting of smooth trenches (peak-to-peak roughness below 2 nm)
  • cutting speeds up to 250 nm/s
  • Environmentally friendly (gold or silver as catalytic material)
  • User friendly (transfer pattern directly from computer to graphene layer)
  • Economically priced (no need for complex high-vacuum installations as is required for electron beam lithography)

Quantum well structure


25.08.2011
| Ref.Nr. 03037
Physics&Engineering

Background
Quantum-well inter-subband devices, such as quantum-well infrared photo-detectors (QWIPs) and quantum cascade lasers (QCLs) are ideal for a variety of ground and space-based applications. Night vision, early warning systems, navigation, flight control systems, weather monitoring, security and surveillance are among the different applications based on QWIPs. QCLs are ideal candidates for the remote sensing of gases in the atmosphere.

Technology
The invention is a quantum well structure including a quantum well layer arranged between two barrier layers. The invention further refers to quantum well photodetectors and quantum cascade laser. 

IP Rights
German Patent DE 103 35 443 B4
US Patent US 7,893,425 B2
European Patent Application

Patent Owner
Humboldt-Universität zu Berlin, Germany

 

Application Area:
Mid-IR Spectroscopic applications, Quantum cascade laser, Quantum-well infrared photodetectors
Development Stage: Prototype
Bild des Benutzers Dr. Kirk Haselton
Licensing Manager: Dr. Kirk Haselton
T +49 30 2125 4842
F +49 30 2125 4822
Market Potential: Security industry, Environmental industry
Benefits:

  • Vertical detection or emission of photons
  • Improved coupling of light into or out of the device
  • High sheet densities
  • Precise control over the subband energies
  • No restrictions on the quantum-well thickness
  • Flexibility in structural design